Nicotinamide riboside - Niagen Bioscience
Alternative Names: NIAGEN; Niagen IV - Niagen Bioscience; nicotinamide riboside chloride; Nicotinamide-beta-riboside; Nicotinamide-ribonucleoside; Nicotinamide-ribose; NRC; SRT-647; Tru Niagen® - Niagen BioscienceLatest Information Update: 13 Aug 2025
At a glance
- Originator Cornell University; Dartmouth College; Washington University
- Developer Ecole Polytechnique Federale de Lausanne.; Emory University; Haukeland University Hospital; National Institutes of Health (USA); Niagen Bioscience; University of Cambridge; University of Iowa; Washington University
- Class Amides; Analgesics; Antivirals; Nicotinic acids; Pyridines; Small molecules; Vitamins
- Mechanism of Action Nicotinamide adenine dinucleotide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Parkinson's disease
- Preclinical Ataxia telangiectasia
- Discontinued Alzheimer's disease; Cockayne syndrome; COVID 2019 infections; Heart failure; Mitochondrial myopathies; Pain; Retinal disorders